Table 1.
EAU Low-Risk PCa n = 297 (28.4%) |
EAU Intermediate-Risk PCa n = 527 (50.3%) |
EAU High-Risk PCa n = 223 (21.3%) |
p-Value | |
---|---|---|---|---|
Age (years) | 65.2 (59.3–69.7) | 65.2 (60.1–70.2) | 67.7 (61.1–71.2) | 0.036 |
BMI (kg/m2) | 26.1 (23.9–28.4) | 25.6 (23.7–27.8) | 25.7 (24.2–28.4) | 0.039 |
ASA physical status | 0.1 | |||
ASA I | 25 (8.4) | 47 (8.9) | 16 (7.2) | |
ASA II | 253 (85.2) | 427 (81.0) | 178 (79.8) | |
ASA III | 19 (6.4) | 53 (10.1) | 29 (13.0) | |
PV (mL) | 40 (30–50) | 38 (30–49) | 40 (30–55) | 0.042 |
PSA (ng/mL) | <0.001 | |||
<10 | 297 (100) | 421 (79.9) | 126 (56.5) | |
10–20 | 0 (0) | 106 (20.1) | 47 (21.1) | |
>20 | 0 (0) | 0 (0) | 50 (22.4) | |
BPC (%) | 26.6 (14.2–41.6) | 28.5 (18.7–47.0) | 42.8 (26.6–62.5) | <0.001 |
Clinical T stage | <0.001 | |||
T1c | 225 (75.8) | 304 (57.7) | 71 (31.8) | |
T2 | 72 (24.2) | 223 (42.3) | 116 (52.0) | |
T3 | 0 (0) | 0 (0) | 36 (16.2) | |
ISUP grade group | <0.001 | |||
ISUP 1 | 297 (100) | 35 (6.6) | 29 (13.0) | |
ISUP 2–3 | 0 (0) | 492 (93.4) | 62 (27.8) | |
ISUP 4–5 | 0 (0) | 0 (0) | 132 (59.2) | |
Clinical N stage | <0.001 | |||
N0 | 297 (100) | 527 (100) | 166 (74.4) | |
N1 | 0 (0) | 0 (0) | 57 (25.6) | |
ePLND performed | <0.001 | |||
No | 207 (69.7) | 155 (29.4) | 19 (8.5) | |
Yes | 90 (30.3) | 372 (70.6) | 204 (91.5) | |
2012 Briganti nomogram score (%) | 2 (1–3) | 3 (2–7) | 12 (5–22) | <0.001 |
Continuous variables are reported as medians (interquartile ranges) while categorical factors are reported as frequencies (percentages). Abbreviations: PCa, prostate cancer; BMI, body mass index; ASA, American Society of Anesthesiologists; PV, prostate volume; PSA, prostate-specific antigen; BPC, biopsy positive cores; ISUP, International Society of Urological Pathology; ePLND, extended pelvic lymph node dissection. Values in bold indicate statistical significance set at p < 0.05.